The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

Trial Profile

The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs PEPIDH1M (Primary)
  • Indications Glioma; Medulloblastoma
  • Focus Adverse reactions
  • Acronyms PRiME
  • Most Recent Events

    • 30 Jan 2018 Planned End Date changed from 1 May 2021 to 1 Jun 2022.
    • 30 Jan 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2019.
    • 30 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top